CataRhex 3® - Strong, Beautiful, Unique – For You

Article

CataRhex 3 ? Phaco without Limits Never before has cutting-edge technology for anterior segment surgery been as easily and reliably available, and never before has its packaging been more compact and tempting.

CataRhex 3® - Strong, Beautiful, Unique – For You

Weighing as little as 5 kg and fitting in any pilot case, CataRhex 3® can be mounted on any IV pole with a click – it is thus the epitome of portable equipment. A device that takes up so little space and is so easy to handle is becoming increasingly attractive in both outpatient and high-volume clinics. After all, CataRhex3® offers the latest phaco technology, from clear lens exchange to the hardest lenses. CataRhex 3 easyPhaco® Technology is available for 1.6, 2.2 and 2.8mm incisions with unparalleled efficiency and chamber stability. The newly developed CortexModeTM makes I/A with capsule cleaning noticeably safer and faster. Anterior vitrectomies can be precisely controlled with the high-precision flow control and the pneumatic Twinac cutting instrument and thanks to the integrated air pressure compressor they are available at all times.

CataRhex 3® is a trend-setter: the HFDS® ab interno function provides MIGS technology which elegantly enables combined glaucoma/phaco surgery. In terms of femto LRCS, too, CataRhex 3® excels with perfect fragment aspiration.

Contact details:
Fabienne Kast, Product Manager Anterior
fabienne.kast@oertli-instruments.comwww.oertli-catarhex3.com

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.